Latest News and Press Releases

ANN ARBOR, Mich., March 28, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2...

ANN ARBOR, Mich., March 23, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that two pooled analyses from four Phase 3 clinical trials of NEXLETOL and results from the Phase 2...

ANN ARBOR, Mich., March 18, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Alan Fuhrman as a Class III director, with a term expiring at the 2022 meeting of...

ANN ARBOR, Mich., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided lipid management franchise updates and financial results for the fourth quarter and year ended December 31,...

–  Bempedoic Acid / Ezetimibe Fixed Dose Combination Tablet is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism  ––  Positive CHMP Opinion is Based...

ANN ARBOR, Mich., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will present at the 38th Annual J.P. Morgan...

ANN ARBOR, Mich., Jan. 03, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on January 2, 2020, the Compensation Committee of Esperion’s Board of Directors granted 358...

ANN ARBOR, Mich., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 20, 2019, the Compensation Committee of Esperion’s Board of Directors granted 61,705...

ANN ARBOR, Mich., Nov. 17, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that pooled analyses from four Phase 3 clinical studies of bempedoic acid were presented at the American...

– 14,032 Patients are Now Fully Enrolled in the CLEAR Cardiovascular Outcomes Trial –– Expect CLEAR Cardiovascular Outcomes Trial to Conclude in the Second Half of 2022 – ANN ARBOR, Mich., Sept. 05,...